{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:37:20Z","timestamp":1792028240157,"version":"4.4.0"},"reference-count":70,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:00:00Z","timestamp":1609200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In recent years, advances in drug therapy for head and neck squamous cell carcinoma (HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as platinum-based drug (cisplatin and carboplatin) and taxane-based drugs (docetaxel and paclitaxel), epidermal growth factor receptor-tyrosine kinase inhibitors (cetuximab) and immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) antibodies (nivolumab and pembrolizumab) have come to be used. The importance of anti-cancer drug therapy is increasing year by year. Therefore, we summarize clinical trials of molecular targeted therapy and biomarkers in HNSCC from previous studies. Here we show the current trends and future prospects of molecular targeted therapy in HNSCC.<\/jats:p>","DOI":"10.3390\/ijms22010240","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T10:04:46Z","timestamp":1609236286000},"page":"240","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":239,"title":["Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9683-6002","authenticated-orcid":false,"given":"Naoya","family":"Kitamura","sequence":"first","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Sento","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumasa","family":"Yoshizawa","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Sasabe","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0392-7720","authenticated-orcid":false,"given":"Yasusei","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Oral Bioscience, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto, Tokushima 770-8504, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): Health-related quality-of-life results from a randomised, phase 3 trial","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"ref_5","first-page":"471","article-title":"Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck","volume":"66","author":"Kish","year":"1982","journal-title":"Cancer Treat. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/cncr.10574","article-title":"Docetaxel\/cisplatin as first-line chemotherapy in patients with head and neck carcinoma","volume":"94","author":"Baur","year":"2002","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/A:1008322415335","article-title":"Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: A phase II study of the Southern Italy Cooperative Oncology Group (SICOG)","volume":"12","author":"Caponigro","year":"2001","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1200\/JCO.2002.20.6.1593","article-title":"Phase II Trial of Docetaxel and Cisplatin Combination Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck","volume":"20","author":"Glisson","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2015.63.1671","article-title":"Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial","volume":"34","author":"Magrini","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_10","first-page":"1046","article-title":"Chemotherapy\/Targeting Therapy for Recurrent\/Metastatic Squamous Cell Carcinoma of the Head and Neck","volume":"47","author":"Sano","year":"2020","journal-title":"Gan To Kagaku Ryoho Cancer Chemother."},{"key":"ref_11","first-page":"1050","article-title":"Treatment of unresectable cases-immune checkpoint inhibitor","volume":"47","author":"Tanaka","year":"2020","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref_12","first-page":"1055","article-title":"Current Clinical Trials for Recurrent or Metastatic Head and Neck Squamous Cell Cancer","volume":"47","author":"Ito","year":"2020","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/annonc\/mdv268","article-title":"Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A multicenter, phase II GORTEC study","volume":"26","author":"Guigay","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/annonc\/mdr367","article-title":"Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck","volume":"23","author":"Hitt","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/annonc\/mdy040","article-title":"Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)","volume":"29","author":"Tahara","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcp.10194","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Simple drugs with a complex mechanism of action?","volume":"194","author":"Normanno","year":"2002","journal-title":"J. Cell. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1200\/JCO.2006.07.2587","article-title":"Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas","volume":"24","author":"Chung","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","article-title":"Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry","volume":"23","author":"Chung","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/jjco\/hyp016","article-title":"A Phase 2 Clinical Trial of Panitumumab Monotherapy in Japanese Patients with Metastatic Colorectal Cancer","volume":"39","author":"Muro","year":"2009","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_20","unstructured":"(2020, December 01). National Comprehensive Cancer Network. NCCN Clinical Practical Guidelines in Oncology. Colon Cancer, version 4. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer","volume":"33","author":"Lenz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/bjc.2015.173","article-title":"Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer","volume":"112","author":"Rowland","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis","volume":"11","author":"Claes","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.2609","article-title":"Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer","volume":"18","author":"Montagut","year":"2012","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jamaoncol.2018.7229","article-title":"HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer","volume":"5","author":"Bregni","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"54627","DOI":"10.18632\/oncotarget.10559","article-title":"MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon","volume":"7","author":"Raghav","year":"2016","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e175245","DOI":"10.1001\/jamaoncol.2017.5245","article-title":"Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses","volume":"4","author":"Montagut","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_29","first-page":"204","article-title":"The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies","volume":"22","author":"Saltz","year":"2003","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2015.61.1509","article-title":"Immunology and Immunotherapy of Head and Neck Cancer","volume":"33","author":"Ferris","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","article-title":"PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer","volume":"73","author":"Badoual","year":"2012","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1158\/0008-5472.CAN-12-2384","article-title":"Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma","volume":"73","author":"Peng","year":"2013","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Corrections to \u201cManagement of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u201d","volume":"28","author":"Haanen","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2019.08.026","article-title":"Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck","volume":"121","author":"Saleh","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"104676","DOI":"10.1016\/j.oraloncology.2020.104676","article-title":"Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck","volume":"105","author":"Kacew","year":"2020","journal-title":"Oral Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104523","DOI":"10.1016\/j.oraloncology.2019.104523","article-title":"Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent\/metastatic head and neck squamous cell carcinoma","volume":"101","author":"Pestana","year":"2020","journal-title":"Oral Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wakasaki, T., Yasumatsu, R., Masuda, M., Takeuchi, T., Manako, T., Matsuo, M., Jiromaru, R., Uchi, R., Komune, N., and Noda, T. (2020). Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12082299"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e000531","DOI":"10.1136\/esmoopen-2019-000531","article-title":"Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors","volume":"4","author":"Iivanainen","year":"2019","journal-title":"ESMO Open"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41571-019-0222-4","article-title":"Tumour-associated neutrophils in patients with cancer","volume":"16","author":"Shaul","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1158\/1078-0432.CCR-19-1372","article-title":"Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade","volume":"25","author":"Georgiadis","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/cas.13486","article-title":"Implementation of \u201cclinical sequencing\u201d in cancer genome medicine in Japan","volume":"109","author":"Kohno","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/cas.13969","article-title":"Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study","volume":"110","author":"Sunami","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-020-1128-z","article-title":"Establishment and characterization of patient-derived cancer models of malignant peripheral nerve sheath tumors","volume":"20","author":"Oyama","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1111\/cas.13730","article-title":"Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0)","volume":"109","author":"Sunami","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"eaan6566","DOI":"10.1126\/scitranslmed.aan6566","article-title":"A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer","volume":"9","author":"Kohsaka","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1158\/2159-8290.CD-NB2019-073","article-title":"AMG 510 First to Inhibit \u201cUndruggable\u201d KRAS","volume":"9","author":"Bishop","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.cell.2017.10.044","article-title":"Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer","volume":"171","author":"Puram","year":"2017","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"104492","DOI":"10.1016\/j.oraloncology.2019.104492","article-title":"Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher","volume":"101","author":"Szturz","year":"2020","journal-title":"Oral Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e001246","DOI":"10.1136\/jitc-2020-001246","article-title":"Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis","volume":"8","author":"Apolo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1841393","DOI":"10.1080\/2162402X.2020.1841393","article-title":"Regulatory approval of photoimmunotherapy: Photodynamic therapy that induces immunogenic cell death","volume":"9","author":"Kepp","year":"2020","journal-title":"OncoImmunology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/nm.2554","article-title":"Cancer cell\u2013selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","volume":"17","author":"Mitsunaga","year":"2011","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Maruoka, Y., Furusawa, A., Okada, R., Inagaki, F., Wakiyama, H., Kato, T., Nagaya, T., Choyke, P.L., and Kobayashi, H. (2020). Interleukin-15 after Near-Infrared Photoimmunotherapy (NIR-PIT) Enhances T Cell Response against Syngeneic Mouse Tumors. Cancers, 12.","DOI":"10.3390\/cancers12092575"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Nishinaga, Y., Sato, K., Yasui, H., Taki, S., Takahashi, K., Shimizu, M., Endo, R., Koike, C., Kuramoto, N., and Nakamura, S. (2020). Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin. Cells, 9.","DOI":"10.3390\/cells9041019"},{"key":"ref_64","first-page":"28","article-title":"Near infrared photoimmunotherapy for cancer","volume":"46","author":"Kobayashi","year":"2019","journal-title":"Jpn. J. Chemother. Gan To Kagaku Ryoho"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1021\/acs.accounts.9b00273","article-title":"Near-Infrared Photoimmunotherapy of Cancer","volume":"52","author":"Kobayashi","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Kobayashi, H., Furusawa, A., Rosenberg, A., and Choyke, P.L. (2020). Near-infrared photoimmunotherapy of cancer: A new approach that kills cancer cells and enhances anti-cancer host immunity. Int. Immunol.","DOI":"10.1093\/intimm\/dxaa037"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.1200\/JCO.2019.37.15_suppl.6014","article-title":"Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC)","volume":"37","author":"Cognetti","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_68","first-page":"1","article-title":"Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials","volume":"4","author":"Cheng","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Castilho, R.M., Squarize, C.H., and Almeida, L.O. (2017). Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071506"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.oraloncology.2012.05.024","article-title":"Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent\/metastatic head and neck cancer","volume":"48","author":"Haigentz","year":"2012","journal-title":"Oral Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/1\/240\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:47:12Z","timestamp":1760179632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/1\/240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,29]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["ijms22010240"],"URL":"https:\/\/doi.org\/10.3390\/ijms22010240","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,29]]}}}